Shinjiro Sato

Shinjiro Sato leads Terumo as President and CEO, overseeing Japan's largest medical device company. Founded in 1921 with the original mission of manufacturing clinical thermometers, Terumo has grown into a global medical technology leader with three core business segments: cardiovascular (interventional catheters, stents, vascular grafts, heart-lung machines), blood and cell technologies (blood bags, apheresis systems, cell therapy processing equipment), and medical care solutions (syringes, infusion pumps, diabetes care). Terumo's cardiovascular business is particularly strong in minimally invasive interventional procedures, including transradial access (performing cardiac catheterization through the wrist rather than the groin — a technique Terumo helped pioneer). The blood and cell technologies division is a global leader in blood component technology and is positioned to benefit from the growing cell therapy market (CAR-T and other advanced therapies require specialized cell processing equipment). The medical device industry benefits from strong secular trends: aging populations globally, rising healthcare spending in emerging markets, and the shift toward minimally invasive procedures. Key stock drivers include cardiovascular device procedure volumes, blood management product demand, cell therapy market growth, yen exchange rate, R&D pipeline and new product launches, geographic expansion (particularly in emerging markets), and competition with Medtronic, Abbott, and Boston Scientific in cardiovascular devices.